Torna a Medicitalia.it oppure fai il LogIn     

Ultimi aggiornamenti da Medicitalia:

Feed RSS Dr. Massimo Martino

Curriculum del Dr. Massimo Martino
 

Curriculum vitae (italiano)

 

 

Pubblicazioni su riviste scientifiche

1.    Plerixafor added to Chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A. Biol Blood Marrow Transplant. 2011 Jul 23. [Epub ahead of print] (impact factor 3.275)

2.    Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. Fedele R, Martino M, Dattola A, Cuzzola M, Irrera G, Messina G, Console G, Iacopino P. Leuk Lymphoma. 2011 Jun 12 (impact factor 2.492)

3.    Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells. Martino M, Massara E, Irrera G, Messina G, Barreca G, Console G. Bone Marrow Transplant. 2011 Apr 4. [Epub ahead of print]  (impact factor 2.998)

4.    Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T, Massara E, Irrera G, Fedele R, Gervasi A, Bresolin G, Iacopino P. Bone Marrow Transplant. 2009 Aug;44(3):163-8. (impact factor 2.998)

5.    Wernicke's encephalopathy after allogeneic stem cell transplantation. Messina G, Quartarone E, Console G, Irrera G, Martino M, Pucci G, Le Piane E, Branca D, Cafarelli F, Gangemi A, Iacopino P. Tumori. 2007 Mar-Apr;93(2):207-9. (impact factor 0.86)

6.    Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells. Martino M, Luise F, Oriana V, Console G, Moscato T, Mammì C, Messina G, Massara E, Irrera G, Piromalli A, Lombardo VT, Laganà C, Iacopino P. Tumori. 2007 Mar-Apr;93(2):155-9. (impact factor 0.86)

7.    Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. Martino M, Console G, Callea V, Stelitano C, Massara E, Irrera G, Messina G, Morabito F, Iacopino P. Eur J Haematol. 2007 Jan;78(1):35-40. (impact factor 2.345)

8.    Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P. Eur J Haematol. 2006 Nov;77(5):410-5 (impact factor 2.345)

9.    Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). Martino M, Callea I, Condemi A, Dattola A, Irrera G, Marcuccio D, Messina G, Pontari A, Pucci G, Console G, Lacopino P. J Clin Apher. 2006 Oct;21(3):169-75. (impact factor 1.471)

10. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P. Am J Hematol. 2006 Dec;81(12):973-8 (impact factor 2.61)

11. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF; Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group. Br J Cancer. 2006 Apr 10;94(7):1016-20. (impact factor 4.346)

12. 'In vivo' time course of plasma myeloperoxidase levels after granulocyte colony-stimulating factor-induced stem cell mobilization. Morabito F, Tomaino A, Cristani M, Martino M, Minciullo PL, Saija A, Gangemi S. Transfus Med. 2005 Oct;15(5):425-8. (impact factor 1.808)

13. Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization. Morabito F, Tomaino A, Cristani M, Cimino F, Martino M, Minciullo PL, Calabrò C, Saija A, Gangemi S. Transfus Apher Sci. 2005 Oct;33(2):141-6 (impact factor 0.970)

14. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Galimberti S, Benedetti E, Morabito F, Fazzi R, Pacini S, Andreazzoli F, Martino M, Iacopino P, Petrini M. Transpl Immunol. 2005 Dec;15(2):173-7(impact factor 2.296)

15. Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Galimberti S, Benedetti E, Morabito F, Petrini I, Battolla B, Papineschi F, Fazzi R, Ciabatti E, Martino M, Cuzzola M, Console G, Iacopino P, Petrini M. Leuk Res. 2006 May;30(5):529-35. (impact factor 2.358)

16.  Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor. Martino M, Morabito F, Callea I, Pontari A, Irrera G, Pucci G, Dattola A, Messina G, Console G, Iacopino P. Transfus Med. 2005 Aug;15(4):323-8 (impact factor 1.808)

17. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, Stelitano C, Andreazzoli F, Guerrini F, Ciabatti E, Martino M, Nobile F, Iacopino P, Petrini M. Leuk Res. 2005 Aug;29(8):961-6. (impact factor 2.358)

18. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. Martino M, Console G, Irrera G, Callea I, Condemi A, Dattola A, Messina G, Pontari A, Pucci G, Furlò G, Bresolin G, Iacopino P, Morabito F. J Clin Apher. 2005 Oct;20(3):129-36. (impact factor 1.471)

19. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Martino M, Oliva E, Console G, Stelitano C, Fujo M, Messina G, Irrera G, Pucci G, Mandaglio R, Callea V, Nobile F, Iacopino P, Morabito F. Support Care Cancer. 2005 Mar;13(3):182-7(impact factor 2.089)

20. High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability. Martino M, Morabito F, Console G, Irrera G, Pucci G, Penna G, Dattola A, Callea I, Pontari A, Condemi A, Messina G, Nardi M, Cicero G, Molica S, Palazzo S, Iacopino P. Tumori. 2003 Sep-Oct;89(5):492-6 (impact factor 0.86)

21. Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Martino M, Morabito F, Console G, Irrera G, Messina G, Pucci G, Nardi M, Nobile F, Molica S, Cicero G, Palazzo S, Peta A, Musolino C, Iacopino P. Tumori. 2003 Jul-Aug;89(4):385-90 (impact factor 0.86)

22. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzará A, Martino M, Benedetti E, Di Raimondo F, Petrini M. Br J Haematol. 2003 Feb;120(3):405-12. (impact factor 4.597)

23. Basiliximab for the treatment of graft rejection in haploidentical peripheral blood stem cell transplantation. Messina G, Quartarone E, Fujo M, Irrera G, Console G, Martino M, Mandaglio R, Morabito F, Iacopino P. Haematologica. 2002 Dec;87(12):ECR4 (impact factor 6.416)

24. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Morabito F, Martino M, Stelitano C, Oliva E, Kropp M, Irrera G, Console G, Fujo M, Messina G, Molica S, Callea V, Iacopino P. Haematologica. 2002 Nov;87(11):1192-9 (impact factor 6.416)

25. Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation. Messina G, Quartarone E, Console G, Cuzzola M, Iacopino O, Martino M, Irrera G, Morabito F, Iacopino P. Haematologica. 2002 Jul;87(7):ECR22 (impact factor 6.416)

26. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. Morabito F, Irrera G, Oliva E, Console G, Martino M, Pucci G, Messina G, Barbaro P, Palazzo S, Iacopino P. Bone Marrow Transplant. 2001 Nov;28(9):883-8 (impact factor 2.998)

 

27. Graft-versus-lymphoma effect in a patient with a refractory low-grade lymphoma. Martino M, Irrera G, Messina G, Pucci G, Morabito F, Iacopino P. Haematologica. 1999 Dec;84(12):1156-7 (impact factor 6.416)

28. High-dose etoposide enables the collection of peripheral blood stem cells in patients who failed cyclophosphamide-induced mobilization. Pucci G, Irrera G, Martino M, Messina G, Console G, Morabito F, Iacopino P. Br J Haematol. 1998 Mar;100(3):612-3 (impact factor 4.597)

29. Two consecutive courses of rh-G-CSF-mobilized peripheral blood stem cells for primary marrow alloengraftment failure: case report. Martino M, Pucci G, Irrera G, Messina G, Morabito F, Iacopino P. Haematologica. 1996 Sep-Oct;81(5):464-7 (impact factor 6.416)

30. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Martino M, Morabito F, Messina G, Irrera G, Pucci G, Iacopino P. Haematologica. 1996 Jan-Feb;81(1):59-61 (impact factor 6.416)

31. Thrombotic thrombocytopenic purpura: a rare late complication of allogeneic bone marrow transplantation. Pucci G, Martino M, Morabito F, Iacopino P, Arcese W, Iori AP, Lombardo VT, L'Abbate A, Santostefano M, Nobile F. Haematologica. 1994 Jul-Aug;79(4):371-3 (impact factor 6.416)

32. Magnetic resonance imaging of the bone marrow in aplastic anemia. Description of a case Tamburrini O, Della Sala M, Sessa M, Pucci G, Martino M. Radiol Med. 1993 Nov;86(5):707-9. (impact factor 6.341)

 


 



 

Condizioni di utilizzo
MEDICITALIA.it propone contenuti a solo scopo informativo che in nessun caso possono costituire la prescrizione di un trattamento, sostituire la visita specialistica o il rapporto diretto con il medico curante. No al fai da te: affidati sempre al tuo medico di fiducia.

Autori e copyright
Per partecipare a Medicitalia ogni professionista invia la documentazione della propria abilitazione professionale.
Tutti i contenuti scientifici sono forniti dai professionisti iscritti.
E' vietata la riproduzione e la divulgazione, anche parziale, senza autorizzazione scritta.

Dichiarazione di conformità alle linee guida emanate dall'Ordine:
Il sottoscritto Dr. Massimo Martino dichiara che il messaggio informativo contenuto nel presente sito è diramato nel rispetto delle linee guida approvate dalla FNOMCeO inerenti l’applicazione degli artt. 55, 56 e 57 del Nuovo Codice di Deontologia Medica.